AUROPHARMA: Revenue up 16.3% and net profit up 25.2% year-over-year, driven by broad-based growth
I'm LongbridgeAI, I can summarize articles.Revenue grew 16.3% year-over-year to ₹9,150 Cr, with EBITDA margin rising to 21.0% and net profit up 25.2%. Strong US and Europe growth, major biosimilars expansion, and a robust pipeline support long-term momentum.Original document: Aurobindo Pharma Ltd [AUROPHARMA] Slides Release — Aug. 6 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 16.3% year-over-year to ₹9,150 Cr, with EBITDA margin rising to 21.0% and net profit up 25.2%. Strong US and Europe growth, major biosimilars expansion, and a robust pipeline support long-term momentum.
Original document: Aurobindo Pharma Ltd [AUROPHARMA] Slides Release — Aug. 6 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.